{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:10:03Z","timestamp":1789035003734,"version":"build-2803163510"},"reference-count":133,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2026.0074","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:27:52Z","timestamp":1789032472000},"source":"Crossref","is-referenced-by-count":0,"title":["Hepatic steatosis: A pandemic disease causing serious secondary diseases"],"prefix":"10.3238","author":[{"given":"Ali","family":"Canbay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Figge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polykarpos C.","family":"Patsalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodor","family":"Baars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa K.","family":"\u00d6z\u00e7\u00fcr\u00fcmez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"G\u00f6tze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"10.3238\/arztebl.m2026.0074_ref1","doi-asserted-by":"crossref","unstructured":"Ludwig J, Viggiano TR, McGill DB, Oh BJ: Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434\u20138","DOI":"10.1016\/S0025-6196(24)00530-5"},{"key":"10.3238\/arztebl.m2026.0074_ref2","doi-asserted-by":"crossref","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al.: A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023; 79: 1542\u201356","DOI":"10.1097\/HEP.0000000000000696"},{"key":"10.3238\/arztebl.m2026.0074_ref3","doi-asserted-by":"crossref","unstructured":"Roeb E, Canbay A, Bantel H, et al.: Amendment \u201eNeue Nomenklatur zur MASLD (Metabolic Dysfunction Associated Steatotic Liver Disease; metabolische Dysfunktion assoziierte steatotische Lebererkrankung)\u201c zur S2k-Leitlinie \u201eNicht-alkoholische Fettlebererkrankung\u201c (v.2.0\/April 2022) der Deutschen Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). Z Gastroenterol 2024; 62: 1077\u201387","DOI":"10.1055\/a-2309-6052"},{"key":"10.3238\/arztebl.m2026.0074_ref4","doi-asserted-by":"crossref","unstructured":"Arita VA, Cabezas MC, Hern\u00e1ndez Vargas JA, et al.: Effects of mediterranean diet, exercise, and their combination on body composition and liver outcomes in metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis of randomized controlled trials. BMC Med 2025; 23: 502","DOI":"10.1186\/s12916-025-04320-7"},{"key":"10.3238\/arztebl.m2026.0074_ref5","unstructured":"DDG: Leitlinien & Praxisempfehlungen: Deutsche Diabetes Gesellschaft e.V. 2026. www.ddg.info\/behandlung-leitlinien\/leitlinien-praxisempfehlungen (last accessed on 18 July 2026)."},{"key":"10.3238\/arztebl.m2026.0074_ref6","doi-asserted-by":"crossref","unstructured":"Mach F, Koskinas KC, Roeters van Lennep JE, et al.: 2025 Focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias: Developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2025; 46: 4359\u201378","DOI":"10.1093\/eurheartj\/ehaf919"},{"key":"10.3238\/arztebl.m2026.0074_ref7","doi-asserted-by":"crossref","unstructured":"Tacke F, Horn P, Wong VWS, et al.: EASL\u2013EASD\u2013EASO Clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol 2024; 81: 492\u2013542","DOI":"10.1016\/j.jhep.2024.04.031"},{"key":"10.3238\/arztebl.m2026.0074_ref8","unstructured":"Pocket-Leitlinie: Dyslipid\u00e4mien (Focused update 2025). 2026. https:\/\/herzmedizin.de\/fuer-aerzte-und-fachpersonal\/dgk\/leitlinien\/leitlinien-katalog\/pocket-leitlinie-dyslipidaemien-focused-update-2025 (last accessed on 18 July 2026)."},{"key":"10.3238\/arztebl.m2026.0074_ref9","doi-asserted-by":"crossref","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L: The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review. Hepatology 2023; 77: 1335\u201347","DOI":"10.1097\/HEP.0000000000000004"},{"key":"10.3238\/arztebl.m2026.0074_ref10","doi-asserted-by":"crossref","unstructured":"Huang DQ, El-Serag HB, Loomba R: Global epidemiology of NAFLD-related HCC: Trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2021; 18: 223\u201338","DOI":"10.1038\/s41575-020-00381-6"},{"key":"10.3238\/arztebl.m2026.0074_ref11","doi-asserted-by":"crossref","unstructured":"Dulai PS, Singh S, Patel J, et al.: Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology 2017; 65: 1557\u201365","DOI":"10.1002\/hep.29085"},{"key":"10.3238\/arztebl.m2026.0074_ref12","doi-asserted-by":"crossref","unstructured":"Hagstr\u00f6m H, Nasr P, Ekstedt M, et al.: Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol 2017; 67: 1265\u201373","DOI":"10.1016\/j.jhep.2017.07.027"},{"key":"10.3238\/arztebl.m2026.0074_ref13","doi-asserted-by":"crossref","unstructured":"Castera L, Rinella ME, Tsochatzis EA: Noninvasive assessment of liver fibrosis. N Engl J Med 2025; 393: 1715\u201329","DOI":"10.1056\/NEJMra2403308"},{"key":"10.3238\/arztebl.m2026.0074_ref14","doi-asserted-by":"crossref","unstructured":"Chen VL, Morgan TR, Rotman Y, et al.: Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance. Hepatology 2025; 81: 312\u201320","DOI":"10.1097\/HEP.0000000000001112"},{"key":"10.3238\/arztebl.m2026.0074_ref15","unstructured":"NHLBI Obesity education initiative expert panel on the identification E: Summary of evidence-based recommendations. In: Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: The evidence report. National Heart, Lung, and Blood Institute; 1998. 2025.www.ncbi.nlm.nih.gov\/books\/NBK2009\/ (last accessed on 10 August 2026)."},{"key":"10.3238\/arztebl.m2026.0074_ref16","doi-asserted-by":"crossref","unstructured":"Catenacci VA, Grunwald GK, Ingebrigtsen JP, et al.: Physical activity patterns using accelerometry in the National Weight Control Registry. Obesity (Silver Spring) 2011; 19: 1163\u201370","DOI":"10.1038\/oby.2010.264"},{"key":"10.3238\/arztebl.m2026.0074_ref17","doi-asserted-by":"crossref","unstructured":"Oh S, So R, Shida T, et al.: High-intensity aerobic exercise improves both hepatic fat content and stiffness in sedentary obese men with nonalcoholic fatty liver disease. Sci Rep 2017; 7: 43029","DOI":"10.1038\/srep43029"},{"key":"10.3238\/arztebl.m2026.0074_ref18","doi-asserted-by":"crossref","unstructured":"Harrison SA, Bedossa P, Guy CD, et al.: A phase 3, randomized, controlled trial of resmetirom in NASH with liver Fibrosis. N Engl J Med 2024; 390: 497\u2013509","DOI":"10.1056\/NEJMoa2309000"},{"key":"10.3238\/arztebl.m2026.0074_ref19","doi-asserted-by":"crossref","unstructured":"Waheed A, Gul MH, Shabbir MUB, et al.: FDA approves resmetirom: Groundbreaking treatment for NASH liver scarring in moderate to advanced fibrosis. Ann Med Surg (Lond) 2024; 87: 1088\u201391","DOI":"10.1097\/MS9.0000000000002770"},{"key":"10.3238\/arztebl.m2026.0074_ref20","unstructured":"Schienkiewitz A, Kuhnert R, Blume M, Mensink GBM: \u00dcbergewicht und Adipositas bei Erwachsenen in Deutschland\u2014Ergebnisse der Studie GEDA 2019\/2020-EHIS. 2022. https:\/\/edoc.rki.de\/handle\/176904\/10231 (last accessed on 18 July 2026)."},{"key":"10.3238\/arztebl.m2026.0074_ref21","doi-asserted-by":"crossref","unstructured":"Pantalone KM, Hobbs TM, Chagin KM, et al.: Prevalence and recognition of obesity and its associated comorbidities: Cross-sectional analysis of electronic health record data from a large US integrated health system. BMJ Open 2017; 7: e017583","DOI":"10.1136\/bmjopen-2017-017583"},{"key":"10.3238\/arztebl.m2026.0074_ref22","doi-asserted-by":"crossref","unstructured":"Labenz C, Huber Y, Michel M, et al.: Impact of NAFLD on the incidence of cardiovascular diseases in a primary care population in Germany. Dig Dis Sci 2020; 65: 2112\u20139","DOI":"10.1007\/s10620-019-05986-9"},{"key":"10.3238\/arztebl.m2026.0074_ref23","doi-asserted-by":"crossref","unstructured":"Yim HE, Yoo KH: Obesity and chronic kidney disease: Prevalence, mechanism, and management. Clin Exp Pediatr 2021; 64: 511\u20138","DOI":"10.3345\/cep.2021.00108"},{"key":"10.3238\/arztebl.m2026.0074_ref24","doi-asserted-by":"crossref","unstructured":"Guo Z, Wu D, Mao R, Yao Z, Wu Q, Lv W: Global burden of MAFLD, MAFLD related cirrhosis and MASH related liver cancer from 1990 to 2021. Sci Rep 2025; 15: 7083","DOI":"10.1038\/s41598-025-91312-5"},{"key":"10.3238\/arztebl.m2026.0074_ref25","doi-asserted-by":"crossref","unstructured":"Zhang H, Zhou XD, Shapiro MD, et al.: Global burden of metabolic diseases, 1990\u20132021. Metabolism 2024; 160: 155999","DOI":"10.1016\/j.metabol.2024.155999"},{"key":"10.3238\/arztebl.m2026.0074_ref26","doi-asserted-by":"crossref","unstructured":"Sanyal AJ, Van Natta ML, Clark J, et al.: Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med 2021; 385: 1559\u201369","DOI":"10.1056\/NEJMoa2029349"},{"key":"10.3238\/arztebl.m2026.0074_ref27","doi-asserted-by":"crossref","unstructured":"Rubino F, Cummings DE, Eckel RH, et al.: Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol 2025; 13: 221\u201362","DOI":"10.1016\/S2213-8587(25)00006-3"},{"key":"10.3238\/arztebl.m2026.0074_ref28","doi-asserted-by":"crossref","unstructured":"Quek J, Chan KE, Wong ZY, et al.: Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2023; 8: 20\u201330","DOI":"10.1016\/S2468-1253(22)00317-X"},{"key":"10.3238\/arztebl.m2026.0074_ref29","doi-asserted-by":"crossref","unstructured":"Jensen EL, Israelsen M, Krag A: Transforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists. Hepatology Communications 2024; 8: e0561","DOI":"10.1097\/HC9.0000000000000561"},{"key":"10.3238\/arztebl.m2026.0074_ref30","doi-asserted-by":"crossref","unstructured":"Arvanitis M, Lowenstein CJ: Dyslipidemia. Ann Intern Med 2023; 176: ITC81\u201396","DOI":"10.7326\/AITC202306200"},{"key":"10.3238\/arztebl.m2026.0074_ref31","doi-asserted-by":"crossref","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, et al.: 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J 2024; 45: 3912\u20134018","DOI":"10.1093\/eurheartj\/ehae646"},{"key":"10.3238\/arztebl.m2026.0074_ref32","doi-asserted-by":"crossref","unstructured":"Dybiec J, Baran W, Dąbek B, et al.: Advances in treatment of dyslipidemia. Int J Mol Sci 2023; 24: 13288","DOI":"10.3390\/ijms241713288"},{"key":"10.3238\/arztebl.m2026.0074_ref33","doi-asserted-by":"crossref","unstructured":"Ray S: Role of statins in the management of dyslipidaemia. Indian Heart J 2024; 76 Suppl 1(Suppl 1): S33\u2013S7","DOI":"10.1016\/j.ihj.2023.11.267"},{"key":"10.3238\/arztebl.m2026.0074_ref34","doi-asserted-by":"crossref","unstructured":"Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP: Statins and non-alcoholic steatohepatitis. J Hepatol 2016; 64: 241\u20132","DOI":"10.1016\/j.jhep.2015.09.021"},{"key":"10.3238\/arztebl.m2026.0074_ref35","unstructured":"Pocket-Leitlinie: Erh\u00f6hter Blutdruck und Hypertonie (Version 2024). 2026. https:\/\/herzmedizin.de\/fuer-aerzte-und-fachpersonal\/dgk\/leitlinien\/leitlinien-katalog\/pocket-leitlinie-erhoehter-blutdruck-und-hypertonie-version-2024 (last accessed on 18 July 2026)."},{"key":"10.3238\/arztebl.m2026.0074_ref36","doi-asserted-by":"crossref","unstructured":"Writing Committee Members, Thompson A, Fleischmann KE, et al.: 2024 AHA\/ACC\/ACS\/ASNC\/HRS\/SCA\/SCCT\/SCMR\/SVM Guideline for perioperative cardiovascular management for noncardiac surgery: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2024; 84: 1869\u2013969","DOI":"10.1016\/j.jacc.2024.06.013"},{"key":"10.3238\/arztebl.m2026.0074_ref37","doi-asserted-by":"crossref","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al.: AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 2023; 77: 1797\u2013835","DOI":"10.1097\/HEP.0000000000000323"},{"key":"10.3238\/arztebl.m2026.0074_ref38","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes*: 6. Glycemic goals, hypoglycemia, and hyperglycemic crises: Standards of care in diabetes\u20142026. Diabetes Care 2025; 49(Supplement 1): 132\u201349","DOI":"10.2337\/dc26-S006"},{"key":"10.3238\/arztebl.m2026.0074_ref39","doi-asserted-by":"crossref","unstructured":"Mellemkj\u00e6r A, Kj\u00e6r MB, Haldrup D, Gr\u00f8nb\u00e6k H, Thomsen KL: Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease. Eur J Intern Med 2024; 122: 28\u201334","DOI":"10.1016\/j.ejim.2023.11.012"},{"key":"10.3238\/arztebl.m2026.0074_ref40","doi-asserted-by":"crossref","unstructured":"Estruch R, Ros E, Salas-Salvad\u00f3 J, et al.: Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med 2018; 378: e34","DOI":"10.1056\/NEJMoa1800389"},{"key":"10.3238\/arztebl.m2026.0074_ref41","unstructured":"Deutsche Adipositas Gesellschaft e. V. https:\/\/adipositas-gesellschaft.de\/ (last accessed on 18 July 2026)."},{"key":"10.3238\/arztebl.m2026.0074_ref42","doi-asserted-by":"crossref","unstructured":"Stepanova M, Henry L, Younossi ZM: Economic burden and patient-reported outcomes of nonalcoholic fatty liver disease. Clin Liver Dis 2023; 27: 483\u2013513","DOI":"10.1016\/j.cld.2023.01.007"},{"key":"10.3238\/arztebl.m2026.0074_ref43","doi-asserted-by":"crossref","unstructured":"Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, et al.: Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: A multi-national cohort study. Gastroenterology 2018; 155: 443\u2013457. e17","DOI":"10.1053\/j.gastro.2018.04.034"},{"key":"10.3238\/arztebl.m2026.0074_ref44","doi-asserted-by":"crossref","unstructured":"Ng CH, Lim WH, Hui Lim GE, et al.: Mortality outcomes by fibrosis stage in nonalcoholic fatty liver disease: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2023; 21: 931\u20139. e5","DOI":"10.1016\/j.cgh.2022.04.014"},{"key":"10.3238\/arztebl.m2026.0074_ref45","doi-asserted-by":"crossref","unstructured":"Aminian A, Al-Kurd A, Wilson R, et al.: Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis. JAMA 2021; 326: 2031\u201342","DOI":"10.1001\/jama.2021.19569"},{"key":"10.3238\/arztebl.m2026.0074_ref46","doi-asserted-by":"crossref","unstructured":"Elsaid MI, Li Y, Bridges JFP, Brock G, Minacapelli CD, Rustgi VK: Association of bariatric surgery with cardiovascular outcomes in adults with severe obesity and nonalcoholic fatty liver disease. JAMA Netw Open 2022; 5: e2235003","DOI":"10.1001\/jamanetworkopen.2022.35003"},{"key":"10.3238\/arztebl.m2026.0074_ref47","doi-asserted-by":"crossref","unstructured":"Zhou H, Luo P, Li P, et al.: Bariatric surgery improves nonalcoholic fatty liver disease: Systematic review and meta-analysis. Obes Surg 2022; 32: 1872\u201383","DOI":"10.1007\/s11695-022-06011-1"},{"key":"10.3238\/arztebl.m2026.0074_ref48","doi-asserted-by":"crossref","unstructured":"Clark JE: A small switch in perspective: Comparing weight loss by nutrient balance versus caloric balance. Biol Sport 2024; 4: 177\u201389","DOI":"10.5114\/biolsport.2024.133666"},{"key":"10.3238\/arztebl.m2026.0074_ref49","doi-asserted-by":"crossref","unstructured":"Strasser B, Spreitzer A, Haber P: Fat loss depends on energy deficit only, independently of the method for weight loss. Ann Nutr Metab 2007; 51: 428\u201332","DOI":"10.1159\/000111162"},{"key":"10.3238\/arztebl.m2026.0074_ref50","doi-asserted-by":"crossref","unstructured":"van der Windt DJ, Sud V, Zhang H, Tsung A, Huang H: The effects of physical exercise on fatty liver disease. Gene Expression 2018; 18: 89\u2013101","DOI":"10.3727\/105221617X15124844266408"},{"key":"10.3238\/arztebl.m2026.0074_ref51","doi-asserted-by":"crossref","unstructured":"Katsagoni CN, Georgoulis M, Papatheodoridis GV, Panagiotakos DB, Kontogianni MD: Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis. Metabolism 2017; 68: 119\u201332","DOI":"10.1016\/j.metabol.2016.12.006"},{"key":"10.3238\/arztebl.m2026.0074_ref52","doi-asserted-by":"crossref","unstructured":"Keating SE, Sabag A, Hallsworth K, et al.: Exercise in the management of metabolic-associated fatty liver disease (MAFLD) in adults: A position statement from exercise and sport science Australia. Sports Med 2023; 53: 2347\u201371","DOI":"10.1007\/s40279-023-01918-w"},{"key":"10.3238\/arztebl.m2026.0074_ref53","doi-asserted-by":"crossref","unstructured":"Keating SE, Hackett DA, George J, Johnson NA: Exercise and non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Hepatol 2012; 57: 157\u201366","DOI":"10.1016\/j.jhep.2012.02.023"},{"key":"10.3238\/arztebl.m2026.0074_ref54","doi-asserted-by":"crossref","unstructured":"Stine JG, DiJoseph K, Pattison Z, et al.: Exercise training is associated with treatment response in liver fat content by magnetic resonance imaging independent of clinically significant body eeight loss in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis. Am J Gastroenterol 2022; 118: 1204\u201313","DOI":"10.14309\/ajg.0000000000002098"},{"key":"10.3238\/arztebl.m2026.0074_ref55","doi-asserted-by":"crossref","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al.: The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol 2012; 107: 811\u201326","DOI":"10.1038\/ajg.2012.128"},{"key":"10.3238\/arztebl.m2026.0074_ref56","doi-asserted-by":"crossref","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al.: Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015; 149: 367\u201378. e5","DOI":"10.1053\/j.gastro.2015.04.005"},{"key":"10.3238\/arztebl.m2026.0074_ref57","unstructured":"Rezdiffra: European Medicines Agency (EMA). 2025. www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rezdiffra (last accessed on 18 July 2026)."},{"key":"10.3238\/arztebl.m2026.0074_ref58","doi-asserted-by":"crossref","unstructured":"Newsome PN, Ambery P: Incretins (GLP-1 receptor agonists and dual\/triple agonists) and the liver. J Hepatol 2023; 79: 1557\u201365","DOI":"10.1016\/j.jhep.2023.07.033"},{"key":"10.3238\/arztebl.m2026.0074_ref59","doi-asserted-by":"crossref","unstructured":"Newsome PN, Loomba R: Therapeutic horizons in metabolic dysfunction\u2013associated steatohepatitis. J Clin Invest. 2025; 135. www.jci.org\/articles\/view\/186425 (last accessed on 18 July 2026)","DOI":"10.1172\/JCI186425"},{"key":"10.3238\/arztebl.m2026.0074_ref60","doi-asserted-by":"crossref","unstructured":"Marcos-Delgado A, Hern\u00e1ndez-Segura N, Fern\u00e1ndez-Villa T, Molina AJ, Mart\u00edn V: The effect of lifestyle intervention on health-related quality of life in adults with metabolic syndrome: A meta-analysis. Int J Environ Res Public Health 2021; 18: 887","DOI":"10.3390\/ijerph18030887"},{"key":"10.3238\/arztebl.m2026.0074_ref61","doi-asserted-by":"crossref","unstructured":"Amiri S, Mahmood N, Junaidi S, Khan MA: Lifestyle interventions improving health-related quality of life: A systematic review and meta-analysis of randomized control trials. J Educ Health Promot 2024; 13: 193","DOI":"10.4103\/jehp.jehp_1156_23"},{"key":"10.3238\/arztebl.m2026.0074_ref62","doi-asserted-by":"crossref","unstructured":"Younossi ZM, Zelber-Sagi S, Henry L, Gerber LH: Lifestyle interventions in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2023; 20: 708\u201322","DOI":"10.1038\/s41575-023-00800-4"},{"key":"10.3238\/arztebl.m2026.0074_ref63","doi-asserted-by":"crossref","unstructured":"Sapmaz A, Paik A, Henry L, Younossi ZM: A comprehensive review of patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease. mtod 2024; 4: N\/A-N\/A","DOI":"10.20517\/mtod.2024.70"},{"key":"10.3238\/arztebl.m2026.0074_ref64","doi-asserted-by":"crossref","unstructured":"Zwaan M de, Hauner H, Holzapfel C, et al.: Interdisziplin\u00e4re S3-Leitlinie zur \u201ePr\u00e4vention und Therapie der Adipositas\u201c der Deutschen Adipositas-Gesellschaft (DAG)\u2014\u00dcberblick \u00fcber die Empfehlungen zu den Themen \u201eStigmatisierung\u201c, \u201eDiagnostik\u201c und \u201eTherapie\u201c. Adipositas\u2014Ursachen, Folgeerkrankungen, Therapie 2025; 19: 84\u2013109","DOI":"10.1055\/a-2552-3990"},{"key":"10.3238\/arztebl.m2026.0074_ref65","doi-asserted-by":"crossref","unstructured":"Dos Santos Borges R, Abreu ES, Berton GG, et al.: Efficacy and safety of GLP-1 receptor agonists in MASH with fibrosis: A systematic review and meta-analysis. JHEP Reports 2026; 8: 101708","DOI":"10.1016\/j.jhepr.2025.101708"},{"key":"10.3238\/arztebl.m2026.0074_ref66","doi-asserted-by":"crossref","unstructured":"Newsome PN, Buchholtz K, Cusi K, et al.: A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 2021; 384: 1113\u201324","DOI":"10.1056\/NEJMoa2028395"},{"key":"10.3238\/arztebl.m2026.0074_ref67","doi-asserted-by":"crossref","unstructured":"Udaikumar J, Nimmagadda R, Lella VV, et al.: The comparative safety and efficacy of resmetirom and semaglutide in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review. Pharmacoepidemiology. 2025; 4. www.mdpi.com\/2813-0618\/4\/3\/14 (last accessed on 18 July 2026)","DOI":"10.3390\/pharma4030014"},{"key":"10.3238\/arztebl.m2026.0074_ref68","doi-asserted-by":"crossref","unstructured":"Sanyal AJ, Newsome PN, Kliers I, et al.: Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med 2025; 392: 2089\u201399","DOI":"10.1056\/NEJMoa2413258"},{"key":"10.3238\/arztebl.m2026.0074_ref69","doi-asserted-by":"crossref","unstructured":"Wilding JPH, Batterham RL, Calanna S, et al.: Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021; 384: 989\u20131002","DOI":"10.1056\/NEJMoa2032183"},{"key":"10.3238\/arztebl.m2026.0074_ref70","doi-asserted-by":"crossref","unstructured":"Gon\u00e7alves J, Urbano Ferreira H, Menino J, et al.: Long-term outcomes of metabolic and bariatric surgery: A 10-year study of effectiveness and predictors. Int J Obes 2026: 1\u20139","DOI":"10.1038\/s41366-026-02039-w"},{"key":"10.3238\/arztebl.m2026.0074_ref71","unstructured":"Sohan PR, Mahakalkar C, Kshirsagar S, et al.: Long-term effectiveness and outcomes of bariatric surgery: A comprehensive review of current evidence and emerging trends. Cureus 2024; 16: e66500"},{"key":"10.3238\/arztebl.m2026.0074_ref72","unstructured":"Nu\u00dfbaumer B, Glechner A, Kaminski-Hartenthaler A, Mahlknecht P, Gartlehner G: Ezetimibe-statin combination therapy. Dtsch Arztebl Int. 2016; 113: 445\u201353"},{"key":"10.3238\/arztebl.m2026.0074_ref73","doi-asserted-by":"crossref","unstructured":"Cho Y, Rhee H, Kim YE, et al.: Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: An open-label randomized controlled trial (ESSENTIAL study). BMC Med 2022; 20: 93","DOI":"10.1186\/s12916-022-02288-2"},{"key":"10.3238\/arztebl.m2026.0074_ref74","doi-asserted-by":"crossref","unstructured":"Drygała S, Radzikowski M, Maciejczyk M: β-blockers and metabolic modulation: Unraveling the complex interplay with glucose metabolism, inflammation and oxidative stress. Front Pharmacol 2024; 15: 1489657","DOI":"10.3389\/fphar.2024.1489657"},{"key":"10.3238\/arztebl.m2026.0074_ref75","doi-asserted-by":"crossref","unstructured":"Yao J, Fan S, Shi X, Gong X, Zhao J, Fan G: Angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers on insulin sensitivity in hypertensive patients: A meta-analysis of randomized controlled trials. PLoS One 2021; 16: e0253492","DOI":"10.1371\/journal.pone.0253492"},{"key":"10.3238\/arztebl.m2026.0074_ref76","doi-asserted-by":"crossref","unstructured":"Bahrmann A, Bahrmann P, Baumann J, et al.: S2k-Leitlinie Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Alter. Diabetologie und Stoffwechsel 2018; 13: 423\u201389","DOI":"10.1055\/a-0666-0820"},{"key":"10.3238\/arztebl.m2026.0074_ref77","doi-asserted-by":"crossref","unstructured":"Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Targher G: Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: An updated meta-analysis of randomized controlled trials. Metabolites 2021; 11: 73","DOI":"10.3390\/metabo11020073"},{"key":"10.3238\/arztebl.m2026.0074_ref78","doi-asserted-by":"crossref","unstructured":"Ge Q, Zhang F, Liu Y: Effect of SGLT2 inhibitors on liver fat content: A meta-analysis. Biomol Biomed 2025; 25: 2647","DOI":"10.17305\/bb.2025.12203"},{"key":"10.3238\/arztebl.m2026.0074_ref79","doi-asserted-by":"crossref","unstructured":"Mantovani A, Byrne CD, Bonora E, Targher G: Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: A meta-analysis. Diabetes Care 2018; 41: 372\u201382","DOI":"10.2337\/dc17-1902"},{"key":"10.3238\/arztebl.m2026.0074_ref80","doi-asserted-by":"crossref","unstructured":"Younossi ZM, Golabi P, de Avila L, et al.: The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol 2019; 71: 793\u2013801","DOI":"10.1016\/j.jhep.2019.06.021"},{"key":"10.3238\/arztebl.m2026.0074_ref81","doi-asserted-by":"crossref","unstructured":"Mantovani A, Csermely A, Petracca G, et al.: Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: An updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2021; 6: 903\u201313.","DOI":"10.1016\/S2468-1253(21)00308-3"},{"key":"10.3238\/arztebl.m2026.0074_ref82","doi-asserted-by":"crossref","unstructured":"Bae JP, Nelson DR, Boye KS, Mather KJ: Prevalence of complications and comorbidities associated with obesity: A health insurance claims analysis. BMC Public Health 2025; 25: 273.","DOI":"10.1186\/s12889-024-21061-z"},{"key":"10.3238\/arztebl.m2026.0074_ref83","doi-asserted-by":"crossref","unstructured":"Fan X, Zhang B, Shi Y, Liu L, Zhao J: Systemic metabolic abnormalities: Key drivers of complications and mortality in MASLD. J Hepatol 2024; 80: e246\u20138.","DOI":"10.1016\/j.jhep.2024.02.001"},{"key":"10.3238\/arztebl.m2026.0074_ref84","doi-asserted-by":"crossref","unstructured":"Zhou XD, Lian LY, Chen QF, et al.: Effect of hypertension on long-term adverse clinical outcomes and liver fibrosis progression in MASLD. J Hepatol 2026; 84: 254\u201365.","DOI":"10.1016\/j.jhep.2025.08.017"},{"key":"10.3238\/arztebl.m2026.0074_ref85","doi-asserted-by":"crossref","unstructured":"de Crecy CA, Yang Q, Liu M, Yin R, Sharma A: Low rates of MASLD screening in young adults with type 2 diabetes: A retrospective cohort study. J Endocr Soc 2026; 10: bvaf223.","DOI":"10.1210\/jendso\/bvaf223"},{"key":"10.3238\/arztebl.m2026.0074_ref86","doi-asserted-by":"crossref","unstructured":"Cao L, An Y, Liu H, et al.: Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: A systematic review and meta-analysis. BMC Med 2024; 22: 101.","DOI":"10.1186\/s12916-024-03315-0"},{"key":"10.3238\/arztebl.m2026.0074_ref87","doi-asserted-by":"crossref","unstructured":"Zhao D, Zheng X, Wang L, Xie Y, Chen Y, Zhang Y: Overlap prevalence and interaction effect of cardiometabolic risk factors for metabolic dysfunction-associated steatotic liver disease. Nutr Metab (Lond) 2025; 22: 10.","DOI":"10.1186\/s12986-025-00903-6"},{"key":"10.3238\/arztebl.m2026.0074_ref88","doi-asserted-by":"crossref","unstructured":"Mertens J, Weyler J, Dirinck E, et al.: Increased prevalence and risk of atherosclerotic cardiovascular disease in individuals with Type 1 diabetes and metabolic dysfunction-associated steatotic liver disease. Cardiovasc Diabetol 2025; 24: 230.","DOI":"10.1186\/s12933-025-02764-y"},{"key":"10.3238\/arztebl.m2026.0074_ref89","doi-asserted-by":"crossref","unstructured":"Josloff K, Beiriger J, Khan A, et al.: Comprehensive review of cardiovascular disease risk in nonalcoholic fatty liver disease. J Cardiovasc Dev Dis 2022; 9: 419.","DOI":"10.3390\/jcdd9120419"},{"key":"10.3238\/arztebl.m2026.0074_ref90","doi-asserted-by":"crossref","unstructured":"Xu T, Zhu W: Association of chronic kidney disease and type 2 diabetes mellitus with metabolic dysfunction-associated steatotic liver disease and liver fibrosis assessed by transient elastography: A cross-sectional study based on NHANES 2017\u20132020. Diabetes Res Clin Pract 2025; 227: 112418.","DOI":"10.1016\/j.diabres.2025.112418"},{"key":"10.3238\/arztebl.m2026.0074_ref91","doi-asserted-by":"crossref","unstructured":"Roderburg C, Krieg S, Krieg A, et al.: Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of chronic kidney disease (CKD). Eur J Med Res 2023; 28: 153.","DOI":"10.1186\/s40001-023-01114-6"},{"key":"10.3238\/arztebl.m2026.0074_ref92","doi-asserted-by":"crossref","unstructured":"Jia X, Zou C, Lu N, Lu Q, Xie C: Obstructive sleep apnea is ralated to metabolic dysfunction associated steatotic liver disease in type 2 diabetes mellitus. Sci Rep 2025; 15: 24627.","DOI":"10.1038\/s41598-025-09985-x"},{"key":"10.3238\/arztebl.m2026.0074_ref93","doi-asserted-by":"crossref","unstructured":"Mitra S, De A, Chowdhury A: Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Transl Gastroenterol Hepatol 2020; 5: 16.","DOI":"10.21037\/tgh.2019.09.08"},{"key":"10.3238\/arztebl.m2026.0074_ref94","doi-asserted-by":"crossref","unstructured":"Younossi Z, Anstee QM, Marietti M, et al.: Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018; 15: 11\u201320.","DOI":"10.1038\/nrgastro.2017.109"},{"key":"10.3238\/arztebl.m2026.0074_ref95","doi-asserted-by":"crossref","unstructured":"Wong VWS, Ekstedt M, Wong GLH, Hagstr\u00f6m H: Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol 2023; 79: 842\u201352.","DOI":"10.1016\/j.jhep.2023.04.036"},{"key":"10.3238\/arztebl.m2026.0074_ref96","doi-asserted-by":"crossref","unstructured":"Canbay A, Kachru N, Haas JS, Sowa JP, Meise D, Ozbay AB: Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2020; 52: 1185\u201394.","DOI":"10.1111\/apt.16016"},{"key":"10.3238\/arztebl.m2026.0074_ref97","doi-asserted-by":"crossref","unstructured":"Kim Y, Rydqvist P, Ramezani T, et al.: Metabolic dysfunction-associated steatohepatitis diagnosis and management in Germany: Insights from an expert consensus panel. Liver Int 2025; 45: e70225.","DOI":"10.1111\/liv.70225"},{"key":"10.3238\/arztebl.m2026.0074_ref98","doi-asserted-by":"crossref","unstructured":"Sanyal AJ, Castera L, Wong VWS: Noninvasive assessment of liver fibrosis in NAFLD. Clin Gastroenterol Hepatol 2023; 21: 2026\u201339.","DOI":"10.1016\/j.cgh.2023.03.042"},{"key":"10.3238\/arztebl.m2026.0074_ref99","doi-asserted-by":"crossref","unstructured":"Jarasvaraparn C, Anderson BP, Tolliver K, Adams KH, Bozic M, Molleston JP: The accuracy of fibrosis score from FibroScan in diverse pediatric liver diseases at a single tertiary center. Dig Liver Dis 2025; 57: 2428\u201334.","DOI":"10.1016\/j.dld.2025.09.033"},{"key":"10.3238\/arztebl.m2026.0074_ref100","doi-asserted-by":"crossref","unstructured":"Rabbat J, Yang B, Lee HW, et al.: Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement. Clin Mol Hepatol 2026; 32: 289\u2013304.","DOI":"10.3350\/cmh.2025.0157"},{"key":"10.3238\/arztebl.m2026.0074_ref101","doi-asserted-by":"crossref","unstructured":"Vali Y, Lee J, Boursier J, et al.: Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. J Hepatol 2020; 73: 252\u201362.","DOI":"10.1016\/j.jhep.2020.03.036"},{"key":"10.3238\/arztebl.m2026.0074_ref102","unstructured":"Younossi ZM, de Avila L, Petta S, et al.: Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study. Hepatology 2025."},{"key":"10.3238\/arztebl.m2026.0074_ref103","unstructured":"Eating & physical activity to lose or maintain weight\u2014NIDDK. 2026. www.niddk.nih.gov\/health-information\/weight-management\/adult-overweight-obesity\/eating-physical-activity (last accessed on 18 July 2026)."},{"key":"10.3238\/arztebl.m2026.0074_ref104","doi-asserted-by":"crossref","unstructured":"Strasser B: Physical activity in obesity and metabolic syndrome. Ann N Y Acad Sci 2013; 1281: 141\u201359.","DOI":"10.1111\/j.1749-6632.2012.06785.x"},{"key":"10.3238\/arztebl.m2026.0074_ref105","doi-asserted-by":"crossref","unstructured":"Andersson K, Karlstr\u00f6m B, Fred\u00e9n S, Petersson H, Ohrvall M, Zethelius B: A two-year clinical lifestyle intervention program for weight loss in obesity. Food Nutr Res 2008; 52.","DOI":"10.3402\/fnr.v52i0.1656"},{"key":"10.3238\/arztebl.m2026.0074_ref106","doi-asserted-by":"crossref","unstructured":"Luo L, Ye J, Zhou T, et al.: Weight-loss plateau during lifestyle intervention predicts treatment response in patients with metabolic dysfunction-associated steatotic liver disease and obesity. Obesity Facts 2025; 18: 321\u201334.","DOI":"10.1159\/000543818"},{"key":"10.3238\/arztebl.m2026.0074_ref107","doi-asserted-by":"crossref","unstructured":"Malespin MH, Barritt AS, Watkins SE, et al.: Weight loss and weight regain in usual clinical practice: Results from the TARGET-NASH observational cohort. Clin Gastroenterol Hepatol 2022; 20: 2393\u20135.","DOI":"10.1016\/j.cgh.2021.01.023"},{"key":"10.3238\/arztebl.m2026.0074_ref108","doi-asserted-by":"crossref","unstructured":"Lemstra M, Bird Y, Nwankwo C, Rogers M, Moraros J: Weight loss intervention adherence and factors promoting adherence: A meta-analysis. Patient Prefer Adherence 2016; 10: 1547\u201359.","DOI":"10.2147\/PPA.S103649"},{"key":"10.3238\/arztebl.m2026.0074_ref109","doi-asserted-by":"crossref","unstructured":"Balakrishnan M, Liu K, Schmitt S, et al.: Behavioral weight-loss interventions for patients with NAFLD: A systematic scoping review. Hepatol Commun 2023; 7: e0224.","DOI":"10.1097\/HC9.0000000000000224"},{"key":"10.3238\/arztebl.m2026.0074_ref110","doi-asserted-by":"crossref","unstructured":"Miranda-Pe\u00f1arroya G, Zer\u00f3n-Rugerio MF, Vallejo-Gracia M, et al.: Adherence to healthy lifestyle habits is a determinant of the effectiveness of weight loss among patients undergoing endoscopic bariatric therapies. Nutrients 2022; 14. www.mdpi.com\/2072-6643\/14\/11\/2261 (last accessed on 18 July 2026).","DOI":"10.3390\/nu14112261"},{"key":"10.3238\/arztebl.m2026.0074_ref111","doi-asserted-by":"crossref","unstructured":"Waheed A, Gul MH, Shabbir MUB, et al.: FDA approves resmetirom: Groundbreaking treatment for NASH liver scarring in moderate to advanced fibrosis. Ann Med Surg (Lond) 2025; 87: 1088\u201391.","DOI":"10.1097\/MS9.0000000000002770"},{"key":"10.3238\/arztebl.m2026.0074_ref112","doi-asserted-by":"crossref","unstructured":"Wharton S, Aronne LJ, Stefanski A, et al.: Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med 2025; 393: 1796\u2013806.","DOI":"10.1056\/NEJMoa2511774"},{"key":"10.3238\/arztebl.m2026.0074_ref113","doi-asserted-by":"crossref","unstructured":"Brandt SJ, Kleinert M, Tsch\u00f6p MH, M\u00fcller TD: Are peptide conjugates the golden therapy against obesity? J Endocrinol 2018; 238: R109\u20139.","DOI":"10.1530\/JOE-18-0264"},{"key":"10.3238\/arztebl.m2026.0074_ref114","doi-asserted-by":"crossref","unstructured":"Ussher JR, Drucker DJ: Glucagon-like peptide 1 receptor agonists: Cardiovascular benefits and mechanisms of action. Nat Rev Cardiol 2023; 20: 463\u201374.","DOI":"10.1038\/s41569-023-00849-3"},{"key":"10.3238\/arztebl.m2026.0074_ref115","doi-asserted-by":"crossref","unstructured":"Loomba R, Hartman ML, Lawitz EJ, et al.: Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med 2024; 391: 299\u2013310.","DOI":"10.1056\/NEJMoa2401943"},{"key":"10.3238\/arztebl.m2026.0074_ref116","doi-asserted-by":"crossref","unstructured":"Sanyal AJ, Bedossa P, Fraessdorf M, et al.: A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med 2024; 391: 311\u20139.","DOI":"10.1056\/NEJMoa2401755"},{"key":"10.3238\/arztebl.m2026.0074_ref117","doi-asserted-by":"crossref","unstructured":"Arconzo M, Piccinin E, Moschetta A: Increased risk of acute liver failure by pain killer drugs in NAFLD: Focus on nuclear receptors and their coactivators. Dig Liver Dis 2021; 53: 26\u201334.","DOI":"10.1016\/j.dld.2020.05.034"},{"key":"10.3238\/arztebl.m2026.0074_ref118","doi-asserted-by":"crossref","unstructured":"Cobbina E, Akhlaghi F: Non-alcoholic fatty liver disease (NAFLD)\u2014 pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev 2017; 49: 197\u2013211.","DOI":"10.1080\/03602532.2017.1293683"},{"key":"10.3238\/arztebl.m2026.0074_ref119","doi-asserted-by":"crossref","unstructured":"Di Ciaula A, Bonfrate L, Krawczyk M, Fr\u00fchbeck G, Portincasa P: Synergistic and detrimental effects of alcohol intake on progression of liver steatosis. Int J Mol Sci 2022; 23: 2636.","DOI":"10.3390\/ijms23052636"},{"key":"10.3238\/arztebl.m2026.0074_ref120","doi-asserted-by":"crossref","unstructured":"Laddha AP, Dzielak L, Lewis C, Xue R, Manautou JE: Impact of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) on the expression and function of hepatobiliary transporters: A comprehensive mechanistic review. Biochim Biophys Acta Mol Basis Dis 2024; 1870: 167037.","DOI":"10.1016\/j.bbadis.2024.167037"},{"key":"10.3238\/arztebl.m2026.0074_ref121","doi-asserted-by":"crossref","unstructured":"Naik A, Belič A, Zanger UM, Rozman D: Molecular interactions between NAFLD and xenobiotic metabolism. Front Genet 2013; 4: 2.","DOI":"10.3389\/fgene.2013.00002"},{"key":"10.3238\/arztebl.m2026.0074_ref122","doi-asserted-by":"crossref","unstructured":"Rey-Bedon C, Banik P, Gokaltun A, et al.: CYP450 drug inducibility in NAFLD via an in vitro hepatic model: Understanding drug-drug interactions in the fatty liver. Biomed Pharmacother 2022; 146: 112377.","DOI":"10.1016\/j.biopha.2021.112377"},{"key":"10.3238\/arztebl.m2026.0074_ref123","doi-asserted-by":"crossref","unstructured":"Kinlen D, Cody D, O\u2019Shea D: Complications of obesity. QJM 2018; 111: 437\u201343.","DOI":"10.1093\/qjmed\/hcx152"},{"key":"10.3238\/arztebl.m2026.0074_ref124","doi-asserted-by":"crossref","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, et al.: Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016; 387: 679\u201390.","DOI":"10.1016\/S0140-6736(15)00803-X"},{"key":"10.3238\/arztebl.m2026.0074_ref125","doi-asserted-by":"crossref","unstructured":"Armstrong MJ, Hull D, Guo K, et al.: Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol 2016; 64: 399\u2013408.","DOI":"10.1016\/j.jhep.2015.08.038"},{"key":"10.3238\/arztebl.m2026.0074_ref126","doi-asserted-by":"crossref","unstructured":"McGowan B, Ciudin A, Baker JL, et al.: A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. Nat Med 2025; 31: 3317\u201329.","DOI":"10.1038\/s41591-025-03978-z"},{"key":"10.3238\/arztebl.m2026.0074_ref127","doi-asserted-by":"crossref","unstructured":"M\u00fcller TD, Bl\u00fcher M, Tsch\u00f6p MH, DiMarchi RD: Anti-obesity drug discovery: Advances and challenges. Nat Rev Drug Discov 2022; 21: 201\u201323.","DOI":"10.1038\/s41573-021-00337-8"},{"key":"10.3238\/arztebl.m2026.0074_ref128","doi-asserted-by":"crossref","unstructured":"Targher G, Byrne CD, Tilg H: MASLD: A systemic metabolic disorder with cardiovascular and malignant complications. Gut 2024; 73: 691\u2013702.","DOI":"10.1136\/gutjnl-2023-330595"},{"key":"10.3238\/arztebl.m2026.0074_ref129","doi-asserted-by":"crossref","unstructured":"Targher G, Tilg H, Byrne CD: Non-alcoholic fatty liver disease: A multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol 2021; 6: 578\u201388.","DOI":"10.1016\/S2468-1253(21)00020-0"},{"key":"10.3238\/arztebl.m2026.0074_ref130","doi-asserted-by":"crossref","unstructured":"Mantovani A, Lonardo A, Stefan N, Targher G: Metabolic dysfunction-associated steatotic liver disease and extrahepatic gastrointestinal cancers. Metabolism 2024; 160: 156014.","DOI":"10.1016\/j.metabol.2024.156014"},{"key":"10.3238\/arztebl.m2026.0074_ref131","doi-asserted-by":"crossref","unstructured":"Zimmet P, Alberti KGMM, Stern N, et al.: The circadian syndrome: Is the metabolic syndrome and much more! J Intern Med 2019; 286: 181\u201391.","DOI":"10.1111\/joim.12924"},{"key":"10.3238\/arztebl.m2026.0074_ref132","unstructured":"Sonnenmoser M: Psychische-erkrankungen-die-innere-uhr-tickt-nicht-bei-jedem-menschen-gleich. Dtsch Arztebl (PP)2022; 21: 271"},{"key":"10.3238\/arztebl.m2026.0074_ref133","doi-asserted-by":"crossref","unstructured":"Schulz-Hanke I: Typ-2-Diabetes\u2014Ist Schichtarbeit ein Risikofaktor? Diabetologie und Stoffwechsel 2015; 10: 114.","DOI":"10.1055\/s-0034-1397829"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2026.0074","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:29:52Z","timestamp":1789032592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2026.0074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":133,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2026.0074","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]}}}